baCta, an innovative French startup, is making waves in the production of astaxanthin, a vibrant antioxidant known for its health benefits in dietary supplements and cosmetics. Cofounded by Marie Rouquette and Mathieu Nohet, the company recently secured €7 million ($8.3 million) in seed funding to enhance its bioproduction platform. This investment, led by LocalGlobe and Daphni, aims to scale up its operations and validate its fermentation processes at a larger capacity.
Harnessing the Power of Robotics and AI
At the heart of baCta’s approach is the integration of generative AI and advanced robotics to optimize yeast strains for astaxanthin production. This process allows for exceptionally rapid strain engineering, positioning baCta as a contender in the biomanufacturing landscape. The company envisions transforming the supply chain by replacing traditional, environmentally taxing methods with biological processes that can achieve similar or lower costs.
The Astaxanthin Advantage
Astaxanthin is extracted primarily from microalgae, which gives marine life its characteristic color. Although it is traditionally produced using petrochemical sources, baCta’s fermentation method offers a more sustainable alternative. Nohet points out the challenges in algae cultivation, such as lower biomass yield and higher contamination risks. By leveraging yeast, which grows faster and can achieve higher cell densities, baCta aims to reduce production costs while maintaining product quality.
Economic Viability in Production
The advantages of yeast fermentation extend beyond growth rates. BaCta has developed a downstream processing (DSP) method that is more cost-effective than current algae-based processes, which often rely on energy-intensive supercritical CO2 extraction methods. This proprietary DSP allows baCta to offer a product that is not only economically competitive but also free from the unpleasant odors associated with some algae-derived ingredients.
Emphasizing Bioavailability
One of the critical factors in the appeal of baCta’s astaxanthin is its bioavailability. Unlike the esterified forms derived from algae, baCta’s yeast-based astaxanthin is unbound, enhancing its absorption in the body. This improved bioavailability could potentially amplify the ingredient’s health benefits, making it an attractive option for nutraceutical and cosmetic applications.
Scaling Up with Strategic Partnerships
Currently, baCta is in advanced discussions with an industrial partner in France to utilize their fermentation facilities for scale-up production. This collaboration is expected to expedite the company’s transition from benchtop experiments to large-scale operations. By leveraging existing fermentation capacities, baCta aims to mitigate capital expenditures while demonstrating profitability.
The Biofoundry Approach to Innovation
BaCta employs an AI-driven biofoundry model that accelerates the engineering of yeast strains. This iterative process involves designing genetic modifications, building new yeast variants, testing their performance, and refining the designs based on data-driven insights. Such a systematic approach not only boosts yield but also enhances overall process efficiency.
- Design: AI models propose genetic edits to enhance astaxanthin production.
- Build: Automated liquid-handling robots create numerous yeast variants in micro-bioreactors.
-
Test: Analytical tools evaluate the performance of various strains in terms of astaxanthin yield.
-
Learn: Performance data informs subsequent design iterations, fostering continuous improvement.
Regulatory Pathways and Future Prospects
As baCta prepares to enter the market, the company is focused on navigating regulatory pathways, including the Generally Recognized as Safe (GRAS) process in the U.S. and the novel food application in the EU. Nohet assures that the final product will comply with non-GMO standards in both regions, ensuring that it meets consumer and regulatory expectations.
Conclusion: A Bright Future for Fermented Ingredients
BaCta’s unique approach to astaxanthin production could signal a significant shift in how the industry views sustainable ingredient sourcing. By combining advanced biotechnology with a commitment to economic viability, baCta is poised to make astaxanthin more accessible and abundant. This innovation may very well herald a new era for fermentation-derived ingredients, challenging traditional synthetic alternatives.
- BaCta has raised €7 million to scale astaxanthin production.
-
The startup utilizes yeast fermentation, promising lower costs and higher bioavailability.
-
An AI-driven biofoundry model accelerates strain engineering and process optimization.
-
Strategic partnerships will support scale-up efforts in production facilities.
-
Regulatory compliance is a priority for market entry in the U.S. and EU.
Read more → agfundernews.com